{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:50:38Z","timestamp":1787759438255,"version":"build-2784847793"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Iterum Therapeutics"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jgar.2025.06.013","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T10:19:45Z","timestamp":1750587585000},"page":"152-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["In vitro activity of sulopenem and comparator agents against US Enterobacterales clinical isolates collected during the SENTRY antimicrobial surveillance program in 2023"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4041-043X","authenticated-orcid":false,"given":"Steven I.","family":"Aronin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Huband","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley A.","family":"Fedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6186-5196","authenticated-orcid":false,"given":"Michael W.","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.06.013_bib0001","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4065\/mcp.2010.0639","article-title":"General principles of antimicrobial therapy","volume":"86","author":"Leekha","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jgar.2025.06.013_bib0002","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.diagmicrobio.2004.05.003","article-title":"Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY antimicrobial surveillance program (1997-2002)","volume":"50","author":"Biedenbach","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2025.06.013_bib0003","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40265-022-01688-1","article-title":"Sulopenem: an intravenous and oral penem for the treatment of urinary tract infections due to multidrug-resistant bacteria","volume":"82","author":"Zhanel","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2025.06.013_bib0004","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1128\/AAC.33.8.1160","article-title":"In vitro activity of CP-65,207, a new penem antimicrobial agent, in comparison with those of other agents","volume":"33","author":"Gootz","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.06.013_bib0005","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1592\/phco.23.14.1497.31937","article-title":"Chemical and microbiologic aspects of penems, a distinct class of beta-lactams: focus on faropenem","volume":"23","author":"Hamilton-Miller","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2025.06.013_bib0006","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1093\/jac\/dkad099","article-title":"In vitro activity of sulopenem and comparator agents against Enterobacterales and Anaerobic clinical isolates collected during the SENTRY antimicrobial surveillance program","volume":"78","author":"Maher","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.06.013_bib0007","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01832-18","article-title":"In vitro activity of sulopenem, an oral penem, against urinary isolates of Escherichia coli","volume":"63","author":"Karlowsky","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.06.013_bib0008","doi-asserted-by":"crossref","first-page":"S417","DOI":"10.1093\/ofid\/ofy210.1194","article-title":"1363. Sulopenem activity against Enterobacteriaceae isolates from patients with urinary tract infection or intraabdominal infection","volume":"5","author":"Puttagunta","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.06.013_bib0009","article-title":"Antimicrobial activity of sulopenem tested against Gram-positive and Gram-negative organisms from the United States and Europe (2013-2015)","author":"Puttagunta","year":"2017","journal-title":"ASM Microbe Poster"},{"key":"10.1016\/j.jgar.2025.06.013_bib0010","doi-asserted-by":"crossref","DOI":"10.5812\/jjm.10887","article-title":"Prevalence of quinolone resistance among extended-spectrum \u03b2-lactamase producing uropathogenic Klebsiella pneumoniae","volume":"7","author":"Raei","year":"2014","journal-title":"Jundishapur J Microbiol"},{"key":"10.1016\/j.jgar.2025.06.013_bib0013","series-title":"M100Ed233. Performance standards for antimicrobial susceptibility testing: 33rd informational supplement","year":"2023"},{"key":"10.1016\/j.jgar.2025.06.013_bib0014","series-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 13.1","year":"2023"},{"key":"10.1016\/j.jgar.2025.06.013_bib0015","series-title":"Antibacterial susceptibility test interpretive criteria","year":"2023"},{"key":"10.1016\/j.jgar.2025.06.013_bib0016","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02359-21","article-title":"Impact of empirical antibiotic therapy on outcomes of outpatient urinary tract infection due to nonsusceptible Enterobacterales","volume":"10","author":"Dunne","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2025.06.013_bib0017","doi-asserted-by":"crossref","first-page":"S473","DOI":"10.1093\/ofid\/ofy210.1356","article-title":"1527. The prevalence of Enterobacteriaceae (ENT) resistant to all major classes of oral antibiotics from outpatient urine cultures in the United States and effect on clinical outcomes","volume":"5","author":"Dunne","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.06.013_bib0018","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/cid\/ciac704","article-title":"Sulopenem or ciprofloxacin for the treatment of uncomplicated urinary tract infections in women: a phase 3, randomized trial","volume":"76","author":"Dunne","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.06.013_bib0019","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/cid\/ciac738","article-title":"Sulopenem for the treatment of complicated urinary tract infections including pyelonephritis: a phase 3, randomized trial","volume":"76","author":"Dunne","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.06.013_bib0020","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.cmi.2024.10.025","article-title":"A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infections","volume":"31","author":"Dunne","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2025.06.013_bib0021","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae631.1295","article-title":"Oral sulopenem\/probenecid for uncomplicated urinary tract infections (uUTI): results from the REASSURE trial","volume":"12","author":"Puttagunta","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.06.013_bib0022","unstructured":"US FDA. Drugs@FDA: FDA-approved drugs. October 25, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/213972s000lbl.pdf."},{"key":"10.1016\/j.jgar.2025.06.013_bib0023","series-title":"Antibacterial susceptibility test interpretive criteria for oral sulopenem etzadroxil and probenecid","year":"2024"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525001456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525001456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:17:18Z","timestamp":1777101438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525001456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":21,"alternative-id":["S2213716525001456"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.06.013","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of sulopenem and comparator agents against US Enterobacterales clinical isolates collected during the SENTRY antimicrobial surveillance program in 2023","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}